Ahmed Kaseb

Credentials: · · · · · ·

History

A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
National Cancer Institute · R01
Contact PI · $3M · University of Tx Md Anderson Can Ctr
2021–2027
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
National Cancer Institute · P50
PI · $11.3M · University of Tx Md Anderson Can Ctr
2019–2026
Novel Point-of-Care Tool to Predict Response to Sorafenib in Hepatocellular Carcinoma
National Cancer Institute · R21
Contact PI · $382.8K · University of Tx Md Anderson Can Ctr
2015–2018
Integrating Plasma IGF-1 into Novel Classification of Hepatocellular Carcinoma
National Cancer Institute · R21
Contact PI · $365.6K · University of Tx Md Anderson Can Ctr
2012–2014

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2021–2027
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2017–2022
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2016–2023
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2013–2020